23rd Apr 2008 07:01
Deltex Medical Group PLC23 April 2008 Deltex Medical Group plc Next generation CardioQ-ODM(TM) monitor released for sale 23 April 2008 - Deltex Medical Group plc ("Deltex Medical" or "the Company"),the UK's leading haemodynamic monitoring company, today announces the release ofthe CardioQ-ODM(TM), the next generation of its market leading oesophagealDoppler monitor (ODM). The CardioQ-ODM offers a number of enhancements over the current model, theCardioQTM • Enhanced patient management and event recording • Upgraded compatibility with hospital networking systems • Expanded data-download options • Faster data processing capability • More memory • Improved user interfaces • Storage of multiple individual users' preferences • Simplified default display, emphasising the measured parameters unique to ODM The CardioQ-ODM is being made available for sale initially in the UK and in theCompany's key markets in Continental Europe, Latin America and the Far East. TheCompany is preparing its application for clearance of the CardioQ-ODM by the USregulatory authorities and expects to release it into the US market in thelatter part of 2008. To support its continuing expansion in the USA in themeantime, the Company intends to use its remaining stocks of CardioQ monitors,supplemented as required by CardioQ units recovered from existing customersunder CardioQ-ODM upgrade schemes. Deltex Medical's Chief Executive, Andy Hill commented: "The launch of the CardioQ-ODM monitor further extends our first-mover advantagein the fast-growing market for technology that allows real-time management ofpatients' circulating blood volumes before, during and after surgery and incritical care. "Our decision to call the new monitor the CardioQ-ODM reflects the perception inglobal medical markets that Deltex Medical is THE oesophageal Doppler monitoringcompany. This is timely, as it is becoming increasingly clear that oesophagealDoppler guided fluid management allows doctors to intervene earlier, more safelyand more effectively than any fluid management protocols that use othertechnologies which do not directly measure blood flow." For further information, please contact:- Deltex Medical Group plc 01243 774 837Nigel Keen, Chairman [email protected] Hill, Chief Executive [email protected] Phillips, Finance Director [email protected] Gavin Anderson & Company 0207 554 1400Deborah Walter [email protected] Speed [email protected] Charles Stanley Securities 020 7149 6000(Nominated Adviser)Philip Davies [email protected] Cook [email protected] Notes for Editors Deltex Medical manufactures and markets the CardioQ-ODM(TM) monitor, which usesdisposable ultra-sound probes inserted into the oesophagus to determine theamount of blood being pumped around the body - 'circulating blood volume'.Reduced circulating blood volume is known as hypovolaemia, which leads toinsufficient oxygen being delivered to the organs. This causes medicalcomplications including peripheral and major organ failure which can lead todeath. Hypovolaemia, which is akin to severe dehydration, affects virtuallyevery patient having surgery because of the combined effects of pre-operativestarvation, the impact of the anaesthetic agents and trauma from the surgeryitself. Using fluids and drugs, guided by the CardioQ-ODM, to optimise theamount of circulating blood significantly reduces post-operative complicationsallowing patients to make a faster, more complete recovery and return homeearlier. The CardioQ-ODM incorporates the Company's proprietary software and a smalldiameter, easy-to-use, minimally invasive, disposable oesophageal probe that isused for transmitting and receiving an ultra-sound signal. By using thistechnology, the CardioQ-ODM provides clinicians with the ability tohaemodynamically optimise critically ill patients and those undergoing routinemoderate to major surgery through the controlled administration of fluid anddrugs. Haemodynamic optimisation has been scientifically proven to improve thespeed and quality of patient recovery and reduce hospital stay. There are already over 1,500 CardioQ-ODMs currently in use in hospitalsworldwide and distribution arrangements are in place in over 30 countries. Inaddition, there are currently more than 100 clinical publications on the use ofthe CardioQ-ODM which have repeatedly:- •Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works •Proved that the CardioQ-ODM works in a wide range of surgical procedures •Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. The SupraQ(TM) is an entirely non-invasive device which uses an ultrasound probeheld at the base of the patient's neck to track the flow of blood in the aorta;it presents the same data as the CardioQ-ODM in a similar format and is used fortaking snapshots or monitoring over short periods. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Deltex Medical